Status Epilepticus - Pipeline Review, H2 2014 competitive analysis

1
Status Epilepticus - Pipeline Review, H2 2014
No. Pages 41
Published on Dec-2014
2
Report Description
Global Markets Directs, Status Epilepticus -
Pipeline Review, H2 2014, provides an overview
of the Status Epilepticuss therapeutic
pipeline. This report provides comprehensive
information on the therapeutic development for
Status Epilepticus, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured
news and press releases. It also reviews key
players involved in the therapeutic development
for Status Epilepticus and special features on
late-stage and discontinued projects. To Get
More Info. Visit http//www.analyzefuture.com/s
tatus-epilepticus-pipeline-review-h2-2014-market
Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
3
Report Description
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. To Enquire About Report _at_
http//www.analyzefuture.com/status-epilepticus-pi
peline-review-h2-2014-market/report-enquiry The
report enhances decision making capabilities and
help to create effective counter strategies to
gain competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products.
4
Table of Content
Table Of ContentsTable of ContentsTable of
Contents 2List of Tables 4List of Figures
4Introduction 5Global Markets Direct Report
Coverage 5Status Epilepticus Overview
6Therapeutics Development 7Pipeline Products
for Status Epilepticus - Overview 7Pipeline
Products for Status Epilepticus - Comparative
Analysis 8Status Epilepticus - Therapeutics
under Development by Companies 9Status
Epilepticus - Therapeutics under Investigation by
Universities/Institutes 10Status Epilepticus -
Pipeline Products Glance 11Clinical Stage
Products 11Early Stage Products 12Unknown Stage
Products 13Status Epilepticus - Products under
Development by Companies 14
5
Table of Content
Status Epilepticus - Products under Investigation
by Universities/Institutes 15Status Epilepticus
- Companies Involved in Therapeutics Development
16Ligand Pharmaceuticals, Inc. 16Sage
Therapeutics 17Status Epilepticus - Therapeutics
Assessment 18Assessment by Monotherapy Products
18Assessment by Target 19Assessment by
Mechanism of Action 21Assessment by Route of
Administration 23Assessment by Molecule Type
25Drug Profiles 26ADD-405008 - Drug Profile
26Product Description 26Mechanism of Action
26RD Progress 26fosphenytoin sodium - Drug
Profile 27Product Description 27Mechanism of
Action 27RD Progress 27SAGE-217 - Drug Profile
28
6
Table of Content
Product Description 28Mechanism of Action 28RD
Progress 28SAGE-547 - Drug Profile 29Product
Description 29Mechanism of Action 29RD
Progress 29SAGE-689 - Drug Profile 31Product
Description 31Mechanism of Action 31RD
Progress 31SGE-102 - Drug Profile 32Product
Description 32Mechanism of Action 32RD
Progress 32Small Molecule to Inhibit GABA
Transaminase for Migraine and Status Epilepticus
- Drug Profile 33Product Description
33Mechanism of Action 33RD Progress 33
7
Table of Content
TG-4155 - Drug Profile 34Product Description
34Mechanism of Action 34RD Progress 34Status
Epilepticus - Recent Pipeline Updates 35Status
Epilepticus - Dormant Projects 38Status
Epilepticus - Product Development Milestones
39Featured News Press Releases 39Apr 04,
2013 Sage Therapeutics Presents Clinical Data On
SGE-102 At 4th London-Innsbruck Colloquium On
Status Epilepticus And Acute Seizures Conference
39Appendix 40Methodology 40Coverage
40Secondary Research 40Primary Research
40Expert Panel Validation 40 To Get Complete
TOC Visit at http//www.analyzefuture.com/st
atus-epilepticus-pipeline-review-h2-2014-market/ta
ble-of-contents
8
FOR MORE DETAILS
Visit us at
http//www.analyzefuture.com/
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States.
TELEPHONE [phone] EMAIL
sales_at_analyzefuture.com